Hbm Holdings Ltd - ESG Rating & Company Profile powered by AI
The webpage of Hbm Holdings Ltd was prepared by All Street Sevva using leading NLP. Jump to the end of this webpage for potential risks for Hbm Holdings Ltd based on sector, location and marketcap. Comprehensive Sustainability analysis of Hbm Holdings Ltd can be accessed by logging in.
Hbm Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Hbm Holdings Ltd | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Hbm Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Hbm Holdings Ltd report the average age of the workforce?
Sign up for free to unlockDoes Hbm Holdings Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Hbm Holdings Ltd offer flexible work?
Sign up for free to unlockDoes Hbm Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Hbm Holdings Ltd conduct supply chain audits?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Hbm Holdings Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose water use targets?
Sign up for free to unlockDoes Hbm Holdings Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Hbm Holdings Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Hbm Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Hbm Holdings Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Hbm Holdings Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Hbm Holdings Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Hbm Holdings Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose its waste policy?
Sign up for free to unlockDoes Hbm Holdings Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose energy use targets?
Sign up for free to unlockDoes Hbm Holdings Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Hbm Holdings Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Hbm Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9001 for the treatment of asthma; HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.